Lv1
60 积分 2021-01-08 加入
Population Pharmacokinetics of Sotorasib in Healthy Subjects and Advanced Solid Tumor Patients Harboring a KRASG12C Mutation from Phase 1 and Phase 2 Studies
2天前
已完结
Adagrasib versus docetaxel in KRASG12C-mutated non-small-cell lung cancer (KRYSTAL-12): a randomised, open-label, phase 3 trial
3个月前
已完结
Immune-mediated liver injury from checkpoint inhibitors: mechanisms, clinical characteristics and management
3个月前
已完结
Glecirasib with or without cetuximab in previously treated locally advanced or metastatic colorectal cancer with KRASG12C mutation (JAB-21822-1002 and JAB-21822-1007): two open-label, non-randomised phase 1/2 trials
3个月前
已关闭
Sotorasib for previously treated colorectal cancers with KRASG12C mutation (CodeBreaK100): a prespecified analysis of a single-arm, phase 2 trial
3个月前
已完结
D3S-001 in advanced solid tumors with KRASG12C mutations: a phase 1 trial
3个月前
已完结
Efficacy and safety of garsorasib in patients with KRAS G12C-mutated advanced pancreatic cancer
3个月前
已完结
Adagrasib versus docetaxel in KRASG12C-mutated non-small-cell lung cancer (KRYSTAL-12): a randomised, open-label, phase 3 trial
3个月前
已完结
Discovery of Elironrasib (RMC-6291), a Potent and Orally Bioavailable, RAS(ON) G12C-Selective, Covalent Tricomplex Inhibitor for the Treatment of Patients with RAS G12C-Addicted Cancers
4个月前
已完结
RAS-GTP Inhibition Overcomes Acquired Resistance to KRASG12C Inhibitors Mediated by Oncogenic and Wildtype RAS Activation in Non-Small Cell Lung Cancer
4个月前
已完结
皖公网安备34019202002308
